Explore the world of psychedelic research

Papers | Trials | Reports | Events

Access our comprehensive database & reports to stay informed about
the latest developments as psychedelics move from trials to treatments

Human brain changes after first psilocybin use
This pre-print, placebo-controlled, within-subjects neuroimaging study (n=28) of psychedelic-naive participants finds that a single high dose of psilocybin (25mg) produces anatomical and functional brain changes from one hour to one month post-dosing. These include decreased axial diffusivity in prefrontal-subcortical tracts, reduced brain network modularity (linked to improved well-being), and increased cortical signal entropy that predicts long-term psychological benefits. These effects were not observed with a 1 mg placebo dose.
Category: Papers
Published: 2025-07-15
Cross-Species Evidence for Psilocin-Induced Visual Distortions: Apparent Motion Is Perceived by Both Humans and Rats
This cross-species experimental study (n=21 humans; n=10 rats) finds that psilocin (18.2mg/70kg for humans; 0.3mg/kg for rats) impairs the ability to distinguish between static and moving images in both humans and rats. In humans, the impairment aligns with psilocin plasma levels and self-reported hallucination intensity. In rats, the effect is specific to motion perception, providing the first evidence of psilocin-induced visual distortions across species.
Category: Papers
Published: 2025-07-15
Esketamine Monotherapy in Adults With Treatment-Resistant Depression: A Randomized Clinical Trial
This Phase IV randomized controlled trial (n=378) found that esketamine nasal spray (Spravato) monotherapy at both 56mg and 84mg doses significantly reduced depression scores compared to placebo in treatment-resistant depression (TRD) patients at 28 days, with rapid onset of effect observed within 24 hours and moderate effect sizes of 0.48 and 0.63 respectively.
Category: Papers
Published: 2025-07-15
Psilocybin treatment extends cellular lifespan and improves survival of aged mice
This preclinical mouse study (n=58) provides the first experimental evidence that psilocin extends cellular lifespan and that psilocybin promotes increased longevity in aged mice. The findings suggest psilocybin may have geroprotective potential, though the molecular mechanisms remain unclear.
Category: Papers
Published: 2025-07-15
Examining mystical experiences as a predictor of psilocybin-assisted psychotherapy for treatment-resistant depression
This secondary analysis of treatment-resistant depression patients (n=31) with major depressive disorder or bipolar II disorder found that greater mystical experiences during the first 25mg psilocybin dose predicted better antidepressant outcomes, though this relationship was not observed for subsequent doses.
Category: Papers
Published: 2025-07-09
Exploring the Therapeutic Effects of Psychedelics Administered to Military Veterans in Naturalistic Retreat Settings
This observational retreat study (n=58) of military veterans attending psilocybin (n=13) or ayahuasca (n=45) retreats found significant improvements across all eight measured domains four weeks later, with the largest percentage reductions in depression (PHQ-9, 29%) and PTSD symptoms (PCL-5, 26%). Psilocybin outperformed ayahuasca on seven outcomes (ayahuasca led slightly on PTSD), men improved more than women on most scales, and greater baseline severity predicted larger post-retreat gains.
Category: Papers
Published: 2025-07-09
Single-dose (10 mg) psilocybin reduces symptoms in adults with obsessive-compulsive disorder: A pharmacological challenge study
This open-label study (n=19) found that 10mg oral psilocybin produced a significant reduction in OCD symptoms compared to 1mg, with a large effect size (Cohen's d = 0.82) one week after dosing, particularly for compulsions rather than obsessions, though effects diminished over subsequent weeks.
Category: Papers
Published: 2025-07-09
An open-label, dose-escalation trial of psilocybin-assisted therapy for bipolar 2 depression
This pre-print open-label trial (n=14) administered psilocybin (10-25mg) plus psychotherapy to people with bipolar II depression. It was well tolerated (only transient cardio spikes, mild anxiety/nausea/headache, and three temporary hypomania-or-suicidality events) and cut MADRS scores by 13–19 points at 21 days and 14 points at 90 days while boosting quality of life, with no excess mania or psychosis.
Category: Papers
Published: 2025-07-09
Psychedelic Research Recap June 2025
Psychedelic research in June 2025 (146 studies, 18 added to the database) looked at long-term effects of psilocybin therapy for depression, 'meaning of life' after psychedelic use, unblinding effects, and more.
Category: Uncategorized
Published: 2025-07-07
Treatment approaches and efficacy in Psychedelic-Induced Psychosis: A systematic review
This systematic review (n=93 cases) found that psychedelic-induced psychosis, primarily caused by LSD and MDMA, lasted an average of 1.8 weeks and responded much better to second-generation antipsychotics (91% response rate) than first-generation antipsychotics (27% response rate), though one-third of patients later developed schizophrenia spectrum disorders.
Category: Papers
Published: 2025-07-01

Our new report ↗ reveals how to secure reimbursement for psychedelic therapies across
Europe by outlining key challenges and offering clear, practical solutions for market access.

partners

Explore Blossom’s Resources

Interconnected & Contextualized Databases

Discover the most relevant papers, trials, events, companies, and people in our extensive collection of over 5,000 entries and 100,000 data points.

Explore Databases

Our interconnected databases allow you to uncover valuable insights and connections in psychedelic research.

Well-Researched Reports

Navigate the complex psychedelic landscape with our meticulously researched reports, covering 18 essential topics, 14 compounds, and 20 countries.

Explore Reports

Our reports provide a comprehensive overview of the current state and future potential of psychedelics.

Timely Insights

Stay informed about the most recent developments in psychedelic research and implementation with our timely articles and updates.

Explore Insights

Our insights cover a wide range of topics, from groundbreaking studies to regulatory changes and industry trends.

Are you new to psychedelics as medicine? Start with our overview →

Subscribe to The Bloom newsletter

Stay at the forefront of the psychedelic revolution with our weekly email, sent every Tuesday. Packed with the latest research breakthroughs, industry news, and actionable insights, The Bloom newsletter is your essential guide to the world of psychedelics.

Join a growing community of over 3,000 researchers, practitioners, and enthusiasts who rely on The Bloom for accurate, timely, and relevant information.

Stay up-to-date with psychedelic research

  • Weekly psychedelic research newsletter
  • Unlimited browsing on Blossom
  • 2000+ Research Papers (short summaries)
Join

Blossom Pro

  • Unlimited access for one account
  • Full reports & extended research summaries
  • Personal profile priority updates
  • chatBlossom (our chat interface, in development)
Learn More

Cancel anytime

Blossom Business

  • Unlimited access for up to ten accounts
  • All Pro membership benefits, Plus:
  • Company profile priority updates
  • Connect via API (show/remix our data on your platform)
Learn More

Cancel anytime

partners

“Blossom is democratising access to psychedelic research by presenting papers from a broad range of disciplines in an accessible weekly write-up.”

Josh Hardman

Founder, Psychedelic Alpha

“The work that Floris and the Blossom team have done to document, organise and synthesise the emerging psychedelic research has helped me stay up to date with this fast-changing landscape. The Bloom newsletter and databases are indispensable resources for anyone who wants to understand the psychedelic science and medicine landscape.”

Zach Heighney

Founder, The Trip Report

partners

Explore Our Comprehensive Psychedelic Reports

Discover a wealth of knowledge in our comprehensive psychedelic reports.

Clinical Topics

Addiction

Alcohol Use Disorder

Opioid Use Disorder

Smoking

Anxiety

Autism

Borderline

Depression

Bipolar

Postpartum

Suicidality

Treatment-Resistant Depression

Eating Disorders

Pain

Fibromyalgia

Headache Disorders

PTSD

Immunity

Neurocognitive Disorders

Obsessive-Compulsive Disorder

Schizophrenia

Traumatic Brain Injury

More Topics

Chemistry

Creativity

Economics

Equity and Ethics

Public Health, Prevention & Behaviour Change

Healthy Subjects

Microdosing

Music

Neuroscience

Palliative Care

Personality

Population Surveys

Relationships

Safety

Technology

Psychedelic Compounds

2C-X

5-MeO-DMT

Ayahuasca

DMT

Ibogaine

Ketamine

Kratom

LSD

MDMA

Mescaline

Nitrous Oxide

Placebo

Psilocybin

Salvia Divinorum

Countries

United States

United Kingdom

Canada

Australia

Europe

Switzerland

Netherlands

Belgium

Germany

France

Spain

Portugal

Italy

Denmark

Norway

“It is wonderful to receive the Bloom newsletter summarising the latest psychedelics research. With so many exciting studies in the psychedelic space, it can be hard to keep up!”

Anne Katrin Schlag

Acting CEO & Head of Research, Drug Science

“Blossom is my go-to resource for the latest in research. It’s the only site to which I refer people who want a comprehensive search for and thoroughgoing analysis of psychedelic studies and papers.”

Rick Strassman

Clinical Associate Professor of Psychiatry, University of New Mexico School of Medicine
Author, DMT: The Spirit Molecule

Embark on a Journey of Personal Transformation with FLO Coaching

FLO Coaching

FLO Coaching, our sister company, offers a personal touch to psychedelic-assisted growth, complementing Blossom’s mission to drive big-picture changes in the psychedelic space.

Founded by Floris, the creator of Blossom, and his wife, FLO Coaching provides one-on-one coaching sessions with psychedelic substances, all within the legal boundaries of The Netherlands. We create a safe and supportive space for you to explore your inner self, overcome obstacles, and grow in ways you never thought possible. At FLO Coaching, we combine cutting-edge research with a personalized approach, tailoring each session to your unique needs and goals.